Search research articles
Contact Us
Filters
Showing results (181-190 of 221) with videos related to
Page
of 23
Sort By:
Blood
|
September 27, 2019
Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group
Frank G Rücker, Mridul Agrawal, Andrea Corbacioglu, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences
|
August 1, 2022
Bacterial DNAemia in Older Participants and Nonagenarian Offspring and Association With Redox Biomarkers: Results From MARK-AGE Study
Robertina Giacconi, Patrizia D'Aquila, Marco Malavolta, et al.
Mechanisms of Ageing and Development
|
September 16, 2024
Development and validation of cardiometabolic risk predictive models based on LDL oxidation and candidate geromarkers from the MARK-AGE data
Andrei Valeanu, Denisa Margina, Daniela Weber, et al.
Biogerontology
|
July 30, 2025
Cytomegalovirus (CMV), oxidative stress, and inflammation: implications for immunosenescence and age-related diseases in the MARK-AGE population
Laura Cianfruglia, Carlo Fortunato, Gretta Veronica Badillo Pazmay, et al.
Blood Advances
|
March 12, 2024
Third-party fecal microbiota transplantation for high-risk treatment-naïve acute GVHD of the lower GI tract
Zachariah DeFilipp, Ashish V Damania, Haesook T Kim, et al.
Blood Advances
|
September 30, 2024
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin
Frank G Rücker, Lars Bullinger, Sibylle Cocciardi, et al.
Blood Advances
|
April 29, 2022
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications
Hartmut Döhner, Daniela Weber, Julia Krzykalla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2019
Gemtuzumab Ozogamicin in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study
Richard F Schlenk, Peter Paschka, Julia Krzykalla, et al.
Mechanisms of Ageing and Development
|
May 3, 2018
Antioxidants linked with physical, cognitive and psychological frailty: Analysis of candidate biomarkers and markers derived from the MARK-AGE study
M Liset Rietman, Annemieke M W Spijkerman, Albert Wong, et al.
Transplantation and Cellular Therapy
|
December 12, 2024
Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group
Nikolaos Katsivelos, Nikolaos Spyrou, Daniela Weber, et al.
Page
of 23
Search research articles
Search
Showing results (181-190 of 221) with videos related to
Sort By:
Page
of 23
Blood
|
September 27, 2019
Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group
Frank G Rücker, Mridul Agrawal, Andrea Corbacioglu, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences
|
August 1, 2022
Bacterial DNAemia in Older Participants and Nonagenarian Offspring and Association With Redox Biomarkers: Results From MARK-AGE Study
Robertina Giacconi, Patrizia D'Aquila, Marco Malavolta, et al.
Mechanisms of Ageing and Development
|
September 16, 2024
Development and validation of cardiometabolic risk predictive models based on LDL oxidation and candidate geromarkers from the MARK-AGE data
Andrei Valeanu, Denisa Margina, Daniela Weber, et al.
Biogerontology
|
July 30, 2025
Cytomegalovirus (CMV), oxidative stress, and inflammation: implications for immunosenescence and age-related diseases in the MARK-AGE population
Laura Cianfruglia, Carlo Fortunato, Gretta Veronica Badillo Pazmay, et al.
Blood Advances
|
March 12, 2024
Third-party fecal microbiota transplantation for high-risk treatment-naïve acute GVHD of the lower GI tract
Zachariah DeFilipp, Ashish V Damania, Haesook T Kim, et al.
Blood Advances
|
September 30, 2024
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin
Frank G Rücker, Lars Bullinger, Sibylle Cocciardi, et al.
Blood Advances
|
April 29, 2022
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications
Hartmut Döhner, Daniela Weber, Julia Krzykalla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2019
Gemtuzumab Ozogamicin in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study
Richard F Schlenk, Peter Paschka, Julia Krzykalla, et al.
Mechanisms of Ageing and Development
|
May 3, 2018
Antioxidants linked with physical, cognitive and psychological frailty: Analysis of candidate biomarkers and markers derived from the MARK-AGE study
M Liset Rietman, Annemieke M W Spijkerman, Albert Wong, et al.
Transplantation and Cellular Therapy
|
December 12, 2024
Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group
Nikolaos Katsivelos, Nikolaos Spyrou, Daniela Weber, et al.
Page
of 23